$Novo-Nordisk A/S(NVO)$ This feels undervalued compared to $Eli Lilly(LLY)$ LLY. Little debt, yearly earnings exceeding 50B (10x that of LLY for ‘23). I get LLY has other drugs in the pipeline aside from weight loss / diabetes, but they don’t seem as lucrative as the weight loss market. Anyone know why else LLY is valued much higher other than the fact it’s a US company? Not saying comparatively LLY is a bad choice, just that NVO books look better. LLY sales as much as PFE and its value is like 5X of PFE. NVO seems slightly undervalued but LLY definitely way overvalued.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
